Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

| More on:
Six smiling health workers pose for a selfie.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Telix Pharmaceuticals Ltd (ASX: TLX) shares are ending the week on a positive note.

In morning trade on Friday, the ASX 200 healthcare stock is up 4.5% to a record high of $27.00.

Why is this ASX 200 healthcare stock racing higher?

Investors have been bidding the radiopharmaceuticals company's shares higher this morning following the release of an update on its Illuccix product.

Illuccix is a prescription radioactive diagnostic agent that is prepared by a healthcare provider and, then injected. It is used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive. It has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada.

Well, it is time to add another regulatory body to the approval list. That's because this morning the ASX 200 healthcare stock revealed that it has received a positive decision on the Marketing Authorization Application (MAA) for the prostate cancer PET1 imaging agent Illuccix, which was submitted in Europe via a decentralised procedure (DCP).

According to the release, this significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM2 as Reference Member State (RMS).

Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS) agree that Illuccix should receive marketing authorisation. The DCP regulatory process will now transition into an administrative national phase to implement authorisations to facilitate commercial launch in each country.

The company notes that PSMA-PET imaging represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT6 scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR).

European guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP).

'Delighted'

The ASX 200 healthcare stock's, chief executive officer of Precision Medicine, Kevin Richardson, commented:

We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix. This clinically important prostate cancer imaging modality is currently recommended in international clinical practice guidelines including European Association of Urology (EAU) and European Society for Medical Oncology (ESMO).

If everything goes to plan, this could be a lucrative market for Telix. After all, the company generated US$517 million in sales over the past 12 months (up 55% year on year) outside the region. These sales were predominantly from Illuccix. Adding such a large market could support further strong growth in FY 2025.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »